A Phenylthiazole Derivative Demonstrates Efficacy On Treatment of the Cryptococcosis & Candidiasis in Animal Models
Author(s) -
Nívea Pereira de Sá,
Caroline Miranda de Lima,
Julliana Ribeiro Alves dos Santos,
Marliete Carvalho da Costa,
Patrícia Pimentel de Barros,
Juliana Campos Junqueira,
Jéssica Aparecida Vaz,
Renata Barbosa de Oliveira,
Beth Burgwyn Fuchs,
Eleftherios Mylonakis,
Carlos A. Rosa,
Daniel Assis Santos,
Susana Johann
Publication year - 2018
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.4155/fsoa-2018-0001
Subject(s) - cryptococcosis , medicine , derivative (finance) , animal model , immunology , microbiology and biotechnology , biology , economics , financial economics
Aim: In this work we test 2-(2-(cyclohexylmethylene)hydrazinyl)-4-phenylthiazole (CHT) against Cryptococcus spp. and Candida albicans . Methods: The ability of CHT to act in biofilm and also to interfere with C. albicans adhesion was evaluated, as well as the efficiency of the CHT in cryptococcosis and candidiasis invertebrate and murine models. Results & conclusion: In the present work we verified that CHT is found to inhibit Cryptococcus and C. albicans affecting biofilm in both and inhibited adhesion of Candida to human buccal cells. When we evaluated in vivo , CHT prolonged survival of Galleria mellonella after infections with Cryptococcusgattii , Cryptococcusneoformans or C. albicans and promoted a reduction in the fungal burden to the organs in the murine models. These results demonstrate CHT therapeutic potential.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom